Ruxolitinib discontinuation syndrome: incidence, risk factors, and management in 251 patients with myelofibrosis

Blood Cancer Journal, Published online: 07 January 2021; doi:10.1038/s41408-020-00392-1Ruxolitinib discontinuation syndrome: incidence, risk factors, and management in 251 patients with myelofibrosis

Source: Blood Cancer Journal - January 7, 2021 Category: Hematology Authors: Francesca Palandri Giuseppe Alberto Palumbo Elena Maria Elli Nicola Polverelli Giulia Benevolo Bruno Martino Elisabetta Abruzzese Mario Tiribelli Alessia Tieghi Roberto Latagliata Francesco Cavazzini Micaela Bergamaschi Gianni Binotto Monica Crugnola Ales Source Type: research